Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

被引：20
|
作者：
Kelley, Michael J. [1 ,2 ,3 ]
Jha, Gautam [4 ]
Shoemaker, Debra [2 ]
Herndon, James E., II [2 ]
Gu, Lin [2 ]
Barry, William T. [2 ,5 ]
Crawford, Jeffrey [1 ,2 ]
Ready, Neal [1 ,2 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA
[3] Durham Vet Affairs Med Ctr, Med Serv, Durham, NC USA
[4] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
[5] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
来源：
CANCER INVESTIGATION | 2017年 / 35卷 / 01期
关键词：
Non-small cell lung cancer; Src; gene expression; ERLOTINIB; TRIAL;
D O I：
10.1080/07357907.2016.1253710
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients hadminor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.
引用
收藏
页码：32 / 35
页数：4
相关论文
共 50 条
  • [21] Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
    Spigel, David R.
    Hainsworth, John D.
    Barton, John H.
    Patton, Jeffrey F.
    Zubkus, John D.
    Simons, Lisa
    Griner, Paula
    Burris, Howard A., III
    Greco, F. Anthony
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : 841 - 845
  • [22] Phase I/II study of weekly docetaxel in patients with previously treated non-small cell lung cancer (NSCLC).
    Hirata, T
    Kawashita, F
    Ogawa, E
    Masago, K
    Kato, M
    Takada, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 676S - 676S
  • [23] Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer
    Kazuhiro Yanagihara
    Kenichi Yoshimura
    Miyuki Niimi
    Hiroyasu Yasuda
    Takahiko Sasaki
    Takafumi Nishimura
    Hiroshi Ishiguro
    Shigemi Matsumoto
    Toshiyuki Kitano
    Masashi Kanai
    Akiko Misawa
    Harue Tada
    Satoshi Teramukai
    Tadashi Mio
    Masanori Fukushima
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 913 - 918
  • [24] Randomized Phase II Study of Pemetrexed versus Gefitinib for Patients with Previously Treated Non-Small Cell Lung Cancer
    Hong, Junshik
    Kyung, Sun Young
    Lee, Sang Pyo
    Park, Jeong Woong
    Jung, Sung Hwan
    Sym, Sun Jin
    Park, Jinny
    Cho, Eun Kyung
    Shin, Dong Bok
    Lee, Jae Hoon
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S401 - S401
  • [25] A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Haura, Eric B.
    Ricart, Alejandro D.
    Larson, Timothy G.
    Stella, Philip J.
    Bazhenova, Lyudmila
    Miller, Vincent A.
    Cohen, Roger B.
    Eisenberg, Peter D.
    Selaru, Paulina
    Wilner, Keith D.
    Gadgeel, Shirish M.
    CLINICAL CANCER RESEARCH, 2010, 16 (08) : 2450 - 2457
  • [26] A phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer (NSCLC)
    Scagliotti, Giorgio V.
    Novello, Silvia
    Brahamer, Julie R.
    Govindan, Ramaswamy
    Rosell, Rafael
    Belani, Chandra P.
    Atkins, James N.
    Tye, Lesley
    Chao, Richard
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S470 - S470
  • [27] Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
    Yoshimura, Naruo
    Sawa, Kenji
    Nakai, Toshiyuki
    Matsumoto, Yoshiya
    Mitsuoka, Shigeki
    Kimura, Tatsuo
    Asai, Kazuhisa
    Yana, Takashi
    Kawaguchi, Tomoya
    Hirata, Kazuto
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (12): : 613 - 618
  • [28] Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer
    Yanagihara, Kazuhiro
    Yoshimura, Kenichi
    Niimi, Miyuki
    Yasuda, Hiroyasu
    Sasaki, Takahiko
    Nishimura, Takafumi
    Ishiguro, Hiroshi
    Matsumoto, Shigemi
    Kitano, Toshiyuki
    Kanai, Masashi
    Misawa, Akiko
    Tada, Harue
    Teramukai, Satoshi
    Mio, Tadashi
    Fukushima, Masanori
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (05) : 913 - 918
  • [29] A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer
    Ikemura, Shinnosuke
    Naoki, Katsuhiko
    Yasuda, Hiroyuki
    Kawada, Ichiro
    Yoda, Satoshi
    Terai, Hideki
    Sato, Takashi
    Ishioka, Kota
    Arai, Daisuke
    Ohgino, Keiko
    Kamata, Hirofumi
    Miyata, Jun
    Kabata, Hiroki
    Betsuyaku, Tomoko
    Soejima, Kenzo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (04) : 356 - 361
  • [30] Feasibility Study of Nivolumab and Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Shimokawa, T.
    Nakamura, Y.
    Iwasawa, S.
    Miyazaki, K.
    Yamanaka, T.
    Takiguchi, Y.
    Okamoto, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2431 - S2431
12345